Management of Malignant Melanoma with Unknown Breslow Thickness and Negative Lymph Nodes

Surgical Management

The British Journal of Dermatology recommends wide local excision as the primary treatment for malignant melanoma with unknown Breslow thickness, with margins based on clinical assessment of the likely tumor thickness 1, 2, 3
For melanoma in situ, the Annals of Oncology suggests 0.5 cm margins 4
For melanomas likely 1-2 mm thick, the British Journal of Dermatology recommends 1-2 cm margins 1
For melanomas likely 2-4 mm thick, the British Journal of Dermatology recommends 2 cm margins 1
For melanomas likely >4 mm thick, the British Journal of Dermatology recommends 2-3 cm margins 1

The Journal of Clinical Oncology suggests that sentinel lymph node biopsy (SLNB) should be considered for staging purposes, especially if the melanoma is suspected to be >1 mm in thickness based on clinical assessment 5, 6
SLNB provides accurate staging information that can guide further management decisions and eligibility for adjuvant therapy, according to the Journal of Clinical Oncology 5
The British Journal of Dermatology states that patients should understand that SLNB is primarily a staging procedure without proven therapeutic value 7, 2
The surgical risks of SLNB, including approximately 5% morbidity, should be explained to patients, as noted by the British Journal of Dermatology 1, 2

The Journal of the American Academy of Dermatology recommends against baseline radiologic imaging for asymptomatic patients with clinically node-negative melanoma 8, 4
Imaging studies should be performed only to evaluate specific signs or symptoms of potential metastasis, according to the Annals of Oncology and the Journal of the American Academy of Dermatology 9, 8

The Journal of the American Academy of Dermatology recommends regular clinical follow-up as the primary surveillance strategy 8
Ultrasound of the regional lymph node basin should be considered in cases where the patient meets criteria for SLNB but does not undergo the procedure, or if SLNB is not technically successful, as suggested by the Journal of the American Academy of Dermatology 8

Elective lymph node dissection is not recommended in the absence of clinically evident nodal disease, according to the British Journal of Dermatology and the Annals of Oncology 1, 2, 9
In cases where SLNB reveals positive nodes, completion lymph node dissection should be considered, as recommended by the Journal of Clinical Oncology 5, 6

Clinical trials should be considered for eligible patients, particularly those with higher-risk features, according to the Journal of the National Comprehensive Cancer Network 3